Prices delayed ≤15 min
About Baxter International Inc.
Baxter International Inc., operating globally via its subsidiaries, is a leading developer and provider of a wide spectrum of healthcare products. The company's comprehensive portfolio includes various dialysis treatments, such as peritoneal and hemodialysis, along with related therapies and services. It also specializes in intravenous (IV) therapies, infusion pumps, administration sets, and devices for drug reconstitution. Further expanding its pharmaceutical offerings, Baxter delivers pre-mixed and oncology drug platforms, inhaled anesthetic agents, critical care products, and pharmacy compounding services. Nutritional support is provided through its parenteral nutrition therapies and associated products. For surgical procedures, the company develops biological products and medical devic
Frequently Asked Questions about BAX
What does Baxter International Inc. (BAX) do?
Baxter International Inc. is a prominent player in the healthcare sector, specializing in medical instruments and supplies. The company is particularly known for its extensive range of dialysis treatments, including both peritoneal and hemodialysis, as well as related therapies and services.
Is BAX stock a good investment in 2026?
Given Baxter's strong position in the healthcare market and its innovative product offerings, it could be viewed as a solid investment for 2026. However, without specific revenue growth or valuation metrics available, potential investors should consider the overall market trends and Baxter's competitive landscape.
What is Baxter International Inc.'s market capitalisation and stock price?
Currently, Baxter International Inc.'s market capitalisation and stock price are not available. Additionally, the 52-week high and low prices are also unspecified, making it difficult to assess its market position.
Does BAX pay dividends to shareholders?
Baxter International Inc. does not currently pay dividends to its shareholders. Instead, the company seems to focus on reinvesting its earnings into growth opportunities and product development.
How profitable is Baxter International Inc.?
Details regarding Baxter's profitability metrics such as net income, margins, ROE, and free cash flow are not available at this time. This lack of data makes it challenging to assess the company's overall financial health.
What is BAX's P/E ratio and is the stock overvalued?
Baxter International Inc. does not have a reported P/E ratio, which complicates any valuation analysis. Without this key metric, it's difficult to determine if the stock is overvalued compared to its peers in the healthcare sector.
How much debt does Baxter International Inc. have?
Information regarding Baxter's debt levels and debt-to-equity ratio is currently not available. This absence of data makes it hard to evaluate the company's balance sheet health and financial stability.
What is BAX's 52-week trading range?
Baxter International Inc.'s 52-week trading range is not specified, nor are the current price and moving averages available. This lack of information hinders a complete analysis of the stock's performance over the past year.
Is BAX a growth stock or value stock?
Without specific data on revenue growth or EPS growth, it's difficult to classify Baxter International Inc. as either a growth or value stock. Investors should look for future earnings potential and market trends to make this determination.
What are the main risks of investing in BAX?
Investing in Baxter International Inc. carries certain risks, including its beta of 0.64, indicating lower volatility compared to the market. Additionally, potential investors should consider sector-specific risks, competition, and the absence of detailed financial metrics.